Page last updated: 2024-10-15

deoxyguanosine triphosphate

Cross-References

ID SourceID
PubMed CID135398599
CHEMBL ID477486
CHEBI ID16497
SCHEMBL ID80609
MeSH IDM0094338

Synonyms (46)

Synonym
CHEBI:16497 ,
2'-deoxyguanosine 5'-(tetrahydrogen triphosphate)
93919-41-6
2'-deoxyguanosine, 5'-triphosphate
[[(2r,3s,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3-hydroxy-tetrahydrofuran-2-yl]methoxy-hydroxy-phosphoryl] phosphono hydrogen phosphate
guanosine 2'-deoxy-, 5'-triphosphate
einecs 219-887-2
DGT ,
5'-dgtp
guanosine, 2'-deoxy-, 5'-(tetrahydrogen triphosphate) (8ci)
guanosine, 2'-deoxy-, 5'-(tetrahydrogen triphosphate)
guanosine 5'-(tetrahydrogen triphosphate), 2'-deoxy- (9ci)
6h-purin-6-one, 2-amino-9-[2-deoxy-5-o-[hydroxy[[hydroxy(phosphonooxy)phosphinyl]oxy]phosphinyl]-beta-d-erythro-pentofuranosyl]-3,9-dihydro-
guanosine 5'-(tetrahydrogen triphosphate), 2'-deoxy-
guanosine, 2'-deoxy-, 5'-triphosphate (6ci,7ci)
guanosine, 2'-deoxy-, 5'-triphosphate
2'-deoxy-5'-gtp
({[({[(2r,3s,5r)-5-(2-amino-6-oxo-6,9-dihydro-3h-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy}(hydroxy)phosphoryl)oxy](hydroxy)phosphoryl}oxy)phosphonic acid
bdbm21687
2'-deoxyguanosine 5'-triphosphate
2564-35-4
C00286
deoxyguanosine triphosphate
deoxy-gtp
DGTP ,
2'-deoxyguanosine-5'-triphosphate
deoxyguanosine 5'-triphosphate
DB02181
2'-deoxyguanosine triphosphate
BMSE000210
CHEMBL477486
unii-8c2o37y44q
8c2o37y44q ,
EPITOPE ID:149169
SCHEMBL80609
HAAZLUGHYHWQIW-KVQBGUIXSA-N
deoxyguanosine triphosphate
2'-deoxyguanosine 5'-triphosphate sodium salt
J-011806
Q424586
9-[2-deoxy-5-o-(hydroxy{[hydroxy(phosphonooxy)phosphoryl]oxy}phosphoryl)pentofuranosyl]-2-imino-3,9-dihydro-2h-purin-6-ol
DTXSID60948499
[[(2r,3s,5r)-5-(2-amino-6-oxo-1h-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] phosphono hydrogen phosphate
HY-138616
CS-0159318
AKOS040757853

Toxicity

ExcerptReference
" To test for additional toxic mechanisms of dG, we selected a double mutant of the mouse T-lymphoma S-49 cell line, dGuo-L, which is deficient in PNP and partially resistant to dGTP feedback inhibition of RR."( Mechanisms of 2'-deoxyguanosine toxicity in mouse T-lymphoma cells with purine nucleoside phosphorylase deficiency and resistance to inhibition of ribonucleotide reductase by dGTP.
Duan, DS; Hoshino, T; Nagashima, T; Pawlak, K; Sadee, W; Waldman, F, 1990
)
" These results suggest that the depletion of GTP rather than that of dGTP produces toxic effects in S-49 cells and that GTP is required for DNA synthesis."( Guanine nucleotide depletion and toxicity in mouse T lymphoma (S-49) cells.
Cohen, MB; Maybaum, J; Sadee, W, 1981
)
" The predominant mechanism underlying its toxic action is thought to be inhibition of thymidylate synthetase (TS), and hence thymidine triphosphate (dTTP) synthesis, resulting in alteration of the balance of deoxynucleotide (dNTP) pools and disruption of DNA synthesis."( Nucleoside-mediated mitigation of 5-fluorouracil-induced toxicity in synchronized murine erythroleukemic cells.
Elstein, KH; Kavlock, RJ; Lau, C; Mole, ML; Rogers, JM; Setzer, RW; Zucker, RM, 1997
)

Pharmacokinetics

ExcerptReference
" Based on these clinical, pharmacokinetic, and pharmacodynamic data, Triapine warrants further study in patients with hematologic malignancies."( Phase I and pharmacodynamic study of Triapine, a novel ribonucleotide reductase inhibitor, in patients with advanced leukemia.
Alvarado, Y; Brown, RA; Cahill, A; Cortes, JE; DiPersio, JF; Faderl, S; Fracasso, PM; Gandhi, V; Garcia-Manero, G; Giles, FJ; Kantarjian, HM; Lambert, P; Plunkett, W; Samson, T; Sznol, M; Thomas, DA; Verstovsek, S; Wright, LP, 2003
)
"To study the effect of mycophenolate mofetil therapy on the pharmacokinetic parameters of a number of antiretroviral drugs, on intracellular pools of deoxycytidine triphosphate (dCTP) and deoxyguanosine triphosphate (dGTP), and on intracellular concentrations of the triphosphate of lamivudine (3TCTP)."( Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Back, DJ; Beijnen, JH; Crommentuyn, KM; Hoggard, PG; Huitema, AD; Kewn, S; Lange, JM; Prins, JM; Sankatsing, SU; Sparidans, RW, 2004
)
"Randomised pharmacokinetic study."( Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Back, DJ; Beijnen, JH; Crommentuyn, KM; Hoggard, PG; Huitema, AD; Kewn, S; Lange, JM; Prins, JM; Sankatsing, SU; Sparidans, RW, 2004
)
" After 8 weeks of therapy, the plasma pharmacokinetic profiles of mycophenolic acid (the active metabolite of mycophenolate mofetil), abacavir, indinavir and nevirapine, and triphosphate concentrations (dCTP, dGTP and 3TCTP) in peripheral blood mononuclear cells, were determined."( Effect of mycophenolate mofetil on the pharmacokinetics of antiretroviral drugs and on intracellular nucleoside triphosphate pools.
Back, DJ; Beijnen, JH; Crommentuyn, KM; Hoggard, PG; Huitema, AD; Kewn, S; Lange, JM; Prins, JM; Sankatsing, SU; Sparidans, RW, 2004
)
" This was the first clinical study in humans to demonstrate the plasma pharmacokinetics and the pharmacodynamic effectiveness of the PNP inhibitor, forodesine; however, regrowth of leukemia cells in the blood and marrow after course 1 suggested that a different therapeutic schedule should be considered for future studies."( A proof-of-principle pharmacokinetic, pharmacodynamic, and clinical study with purine nucleoside phosphorylase inhibitor immucillin-H (BCX-1777, forodesine).
Ayres, M; Bantia, S; Davisson, J; Du, M; Faderl, S; Gandhi, V; Harman, L; Kantarjian, H; Kilpatrick, JM; Plunkett, W; Thomas, D; Wierda, WG, 2005
)

Bioavailability

ExcerptReference
" Oral bioavailability of BCX-34 in rats is 76%."( In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia, S; Johnson, HG; Montgomery, JA; Walsh, GM, 1996
)
" Forodesine is an orally bioavailable PNP inhibitor with picomolar potency."( Preclinical and clinical evaluation of forodesine in pediatric and adult B-cell acute lymphoblastic leukemia.
Balakrishnan, K; Bantia, S; Franklin, A; Gandhi, V; Ravandi, F, 2013
)

Dosage Studied

ExcerptReference
" The results demonstrate that BCX-34 inhibits human PNP and T-cell proliferation, is orally bioavailable in rodents, and pharmacologically active in vivo in rodents after oral dosing with no apparent side effects or toxicity."( In vivo and in vitro pharmacologic activity of the purine nucleoside phosphorylase inhibitor BCX-34: the role of GTP and dGTP.
Bantia, S; Johnson, HG; Montgomery, JA; Walsh, GM, 1996
)
"The difference in binding affinity of tenofovir (more than two orders of magnitude in terms of local concentration), a 30x higher dosage of the (R)-tenofovir enantiomer as compared to conformational isomeric or rotameric adefovir, and the constrained mutational space due to gene overlap in HBV may explain the absence of resistance mutations after 6 years of tenofovir monotherapy."( Differential binding of tenofovir and adefovir to reverse transcriptase of hepatitis B virus.
Berkhout, B; van Hemert, FJ; Zaaijer, HL, 2014
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (6)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
Saccharomyces cerevisiae metaboliteAny fungal metabolite produced during a metabolic reaction in Baker's yeast (Saccharomyces cerevisiae).
Escherichia coli metaboliteAny bacterial metabolite produced during a metabolic reaction in Escherichia coli.
mouse metaboliteAny mammalian metabolite produced during a metabolic reaction in a mouse (Mus musculus).
Arabidopsis thaliana metaboliteAny plant metabolite that is produced by Arabidopsis thaliana.
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
deoxyguanosine phosphate
purine 2'-deoxyribonucleoside 5'-triphosphate
guanyl deoxyribonucleotideA purine 2'-deoxyribonucleotide where the purine is guanine.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (21)

PathwayProteinsCompounds
8-oxo-(d)GTP detoxification I010
superpathway of purine nucleotides de novo biosynthesis I1232
purine deoxyribonucleosides salvage411
superpathway of guanosine nucleotides de novo biosynthesis I46
oxidized GTP and dGTP detoxification18
guanosine deoxyribonucleotides de novo biosynthesis I46
Purine nucleotides and Nucleosides metabolism ( Purine nucleotides and Nucleosides metabolism )10577
ATP + dGDP = ADP + dGTP ( Purine nucleotides and Nucleosides metabolism )73
Purine metabolism1336
The impact of Nsp14 on metabolism (COVID-19 Disease Map)084
8-oxo-(d)GTP detoxification II012
purine nucleotide metabolism (phosphotransfer and nucleotide modification)023
purine nucleotides de novo biosynthesis I039
superpathway of histidine, purine, and pyrimidine biosynthesis064
ESC pluripotency pathways15
Endothelin pathways013
miRNA biogenesis11
Biochemical pathways: part I0466
Hypothetical craniofacial development pathway02
Embryonic stem cell pluripotency pathways05
Purine metabolism and related disorders2353

Protein Targets (2)

Activation Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
DNA polymerase subunit gamma-1Homo sapiens (human)Kd0.80000.80003.40006.0000AID357985
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Kd4.20000.00062.40599.8000AID572771; AID618865
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Other Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Reverse transcriptase/RNaseH Human immunodeficiency virus 1Km0.54000.07001.91446.9000AID711539
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (7)

Processvia Protein(s)Taxonomy
base-excision repair, gap-fillingDNA polymerase subunit gamma-1Homo sapiens (human)
DNA metabolic processDNA polymerase subunit gamma-1Homo sapiens (human)
DNA-templated DNA replicationDNA polymerase subunit gamma-1Homo sapiens (human)
mitochondrial DNA replicationDNA polymerase subunit gamma-1Homo sapiens (human)
base-excision repairDNA polymerase subunit gamma-1Homo sapiens (human)
DNA replication proofreadingDNA polymerase subunit gamma-1Homo sapiens (human)
DNA biosynthetic processDNA polymerase subunit gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
protease bindingDNA polymerase subunit gamma-1Homo sapiens (human)
DNA bindingDNA polymerase subunit gamma-1Homo sapiens (human)
chromatin bindingDNA polymerase subunit gamma-1Homo sapiens (human)
DNA-directed DNA polymerase activityDNA polymerase subunit gamma-1Homo sapiens (human)
protein bindingDNA polymerase subunit gamma-1Homo sapiens (human)
single-stranded DNA 3'-5' DNA exonuclease activityDNA polymerase subunit gamma-1Homo sapiens (human)
3'-5' exonuclease activityDNA polymerase subunit gamma-1Homo sapiens (human)
5'-deoxyribose-5-phosphate lyase activityDNA polymerase subunit gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (6)

Processvia Protein(s)Taxonomy
mitochondrionDNA polymerase subunit gamma-1Homo sapiens (human)
mitochondrial matrixDNA polymerase subunit gamma-1Homo sapiens (human)
gamma DNA polymerase complexDNA polymerase subunit gamma-1Homo sapiens (human)
mitochondrial nucleoidDNA polymerase subunit gamma-1Homo sapiens (human)
intracellular membrane-bounded organelleDNA polymerase subunit gamma-1Homo sapiens (human)
protein-containing complexDNA polymerase subunit gamma-1Homo sapiens (human)
mitochondrionDNA polymerase subunit gamma-1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (22)

Assay IDTitleYearJournalArticle
AID359797Ratio of polymerization constant K to Kd for exonuclase deficient HSV1 DNA polymerase UL42 D368A mutant2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
AID359795Polymerizing activity of exonuclase deficient HSV1 DNA polymerase UL42 D368A mutant assessed as rate of nucleotide incorporation by pre-steady state single turnover assay2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
AID711538Ratio of Vmax to Km for HIV1 reverse transcriptase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID1542234Binding affinity to recombinant C-terminal 6xHis-tagged MTH1 (3 to 156 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as decrease in fluorescence intensity at 1 to 10 uM after 3 mins by tryptophan fluorescence spectrosco2019European journal of medicinal chemistry, Apr-01, Volume: 167Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
AID618865Binding affinity to HIV1 reverse transcriptase assessed as L-3'-azido-NTP incorporation in nascent DNA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID618875Binding affinity to HIV1 reverse transcriptase M184V mutant assessed as L-3'-azido-NTP incorporation in nascent DNA2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID572771Binding affinity to HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID572772Ratio of Kpol to Kd for HIV1 reverse transcriptase2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID28240Half life period in phosphate buffer (pH 7.5) was determined at 37 degrees Centigrade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.
AID359811Ratio of polymerization constant K to Kd for human recombinant DNA polymerase gamma E200A mutant2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
AID18096Kinetic parameter Km was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID1542233Binding affinity to recombinant C-terminal 6xHis-tagged MTH1 (3 to 156 residues) (unknown origin) expressed in Escherichia coli BL21(DE3) cells assessed as decrease in fluorescence intensity at 1 to 200 uM after 3 mins by tryptophan fluorescence spectrosc2019European journal of medicinal chemistry, Apr-01, Volume: 167Discovery of a new class of MTH1 inhibitor by X-ray crystallographic screening.
AID229453Efficiency expressed as ratio of Vmax to that of Km was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID618876Ratio Kpol to Kd for wild type HIV 1 reverse transcriptase2011European journal of medicinal chemistry, Sep, Volume: 46, Issue:9
Synthesis, antiviral activity, cytotoxicity and cellular pharmacology of l-3'-azido-2',3'-dideoxypurine nucleosides.
AID572770Activity at HIV1 reverse transcriptase measured after 30 mins2009Antimicrobial agents and chemotherapy, Sep, Volume: 53, Issue:9
Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides.
AID359796Binding affinity to exonuclase deficient HSV1 DNA polymerase UL42 D368A mutant2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
AID359810Polymerizing activity of exonuclase deficient human recombinant DNA polymerase gamma E200A mutant assessed as rate of nucleotide incorporation by pre-steady state single nucleotide incorporation assay2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
AID28239Half life period in human blood serum was determined at 37 degrees Centigrade2002Journal of medicinal chemistry, Mar-14, Volume: 45, Issue:6
Carbocyclic dinucleoside polyphosphonates: interaction with HIV reverse transcriptase and antiviral activity.
AID711522Activity of HIV1 reverse transcriptase assessed per unit of protein2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID711539Activity of HIV1 reverse transcriptase2011Journal of medicinal chemistry, Apr-28, Volume: 54, Issue:8
Synopsis of some recent tactical application of bioisosteres in drug design.
AID22610Kinetic parameter Vmax was determined2002Bioorganic & medicinal chemistry letters, Jan-07, Volume: 12, Issue:1
2-Amino-7-deazaadenine forms stable base pairs with cytosine and thymine.
AID357985Binding affinity to exonuclase deficient human recombinant DNA polymerase gamma E200A mutant2007The Journal of biological chemistry, Aug-24, Volume: 282, Issue:34
Enzymatic therapeutic index of acyclovir. Viral versus human polymerase gamma specificity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (337)

TimeframeStudies, This Drug (%)All Drugs %
pre-199065 (19.29)18.7374
1990's95 (28.19)18.2507
2000's93 (27.60)29.6817
2010's70 (20.77)24.3611
2020's14 (4.15)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (2.05%)5.53%
Reviews10 (2.93%)6.00%
Case Studies1 (0.29%)4.05%
Observational0 (0.00%)0.25%
Other323 (94.72%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]